The PCDx test is a Next-Generation Sequencing (NGS) based diagnostic genomic test that offers a more targeted, personalized approach to cancer treatment by interrogating and identifying the underlying genomic alterations of your tumor’s DNA & RNA. The information provided by this test assists your treating physician in developing a more informed and individually tailoredtreatment strategy for your cancer.

NGS is a revolutionary laboratory technology that is utilized by Paradigm’s PCDx test to rapidly, accurately and confidently assess genes of a specific tumor sample and identify potentially treatable genomic alterations in your cancer’s DNA & RNA.

Genomic alterations are changes in the tumor’s DNA that can impact the way that specific cells and cancers behave. While most genomic changes are part of our normal biology and do not have a negative impact, some can lead to cancer. While cancers are typically caused by alterations within a few hundred very specific genes, only a sub-set of those genes are classified as “actionable” or associated with a drug therapy. Research has shown that using therapies that “target” these actionable gene alterations can lead to better patient outcomes with fewer side effects.

The results of your genomic testing will be sent to your treating physician in a clinical report, which will outline: The testing performed The genomic alterations that were identified Information on any potential treatment strategies, including clinical trials that could be of benefit based on your tumor’s analysis. Your physician may incorporate this data as they develop your individualized treatment strategy.